Migraine is a neurological condition that can cause multiple symptoms such as severe, recurring, and painful headaches.
The global migraine drugs market is expected to register significant growth in the forecoming years. Major factors driving growth of the global migraine drugs markets are, increasing prevalence of migraine. In addition, instances of chronic and lifestyle diseases, changing life style, rising consumption of unhealthy food are the factors boosting the demand for migraine drugs.
The global migraine drugs market report has been segmented on the basis of treatment, route of administration, distribution channel, and region.
On the basis of treatment, the global migraine drugs market has been segmented into abortive or acute and prophylactic or preventive.
On the basis of route of administration, the global migraine drugs market has been segmented into oral, injectable, and others includes nasal spray, transdermal patch, etc.
On the basis of region, the global migraine drugs markets segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Request for the Sample Report Here: https://marketresearch.biz/report/migraine-drugs-market/request-sample/
In 2018, North America migraine drugs market is expected to account for major share in the global market in terms of revenue, and is expected to maintain its dominance over the forecast period. This is primarily attributed, due increasing incidence of chronic diseases and disorders in the region. However, Asia Pacific migraine drugs market is projected to register highest CAGR in the next five years, due to demand for better quality therapy and number of health conscious population in the region.
Key players operating in the global migraine drugs market include AstraZeneca Plc., Allergan Plc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Eli Lilly & Co., Novartis AG, Merck & Co., Inc., Valeant Pharmaceutical International, Inc., and Janssen Pharmaceutical Company (Johnson & Johnson).